LambdaVision, a biotechnology company developing a protein-based artificial retina to restore vision for patients affected by retinal degenerative diseases, announced it has raised $7 million in seed funding. The round was co-led by Seven Seven Six and Aurelia Foundry Fund, with additional support from Seraphim Space. The funding provides operational runway into 2027 and will support preclinical development, scale-up of manufacturing, and preparation for clinical trials.
The company is focused on helping patients with conditions such as retinitis pigmentosa and age-related macular degeneration, which affect millions worldwide and currently have limited effective treatment options. LambdaVision’s approach uses microgravity environments aboard the International Space Station to manufacture uniform, multilayered protein-based retinal implants. These artificial retinas are designed to mimic the light-absorbing function of photoreceptor cells and activate remaining neural pathways in the eye.
LambdaVision has conducted nine missions in partnership with NASA and Space Tango, refining its microgravity-enabled manufacturing process. The company has also secured more than $15 million in non-dilutive funding from NASA, the National Science Foundation, and the National Eye Institute. This foundation positions LambdaVision to expand production capacity and prepare for clinical evaluation of its artificial retina.
The company plans to continue fundraising ahead of a future Series A. The announcement aligns with CEO Nicole Wagner’s participation in the Payload Investors Summit, where she will speak on the role of biomanufacturing and space-based infrastructure in advancing human health.
KEY QUOTES:
“Support from Seven Seven Six, Aurelia Foundry Fund, Seraphim Space, and other investors in the round underscores the growing recognition of the potential for space-based biomanufacturing to accelerate the development of life-changing therapies on Earth. This seed round funding will help bring us closer to clinical trials and continue to pioneer scalable production of our artificial retina, including manufacturing techniques implemented in low-Earth orbit.”
Nicole Wagner, Ph.D., CEO of LambdaVision
“LambdaVision is redefining what’s possible at the intersection of space and human health. Their mission to restore vision through space-based biotechnology is deeply meaningful to me and a powerful example of how innovation beyond our planet can transform lives here on Earth. At Seven Seven Six, we’re proud to back founders who turn scientific breakthroughs into lasting human impact—and LambdaVision is doing exactly that.”
Katelin Holloway, Founding Partner at Seven Seven Six
“LambdaVision is a perfect example of how the microgravity environment can unlock groundbreaking advances in human health. Their pioneering work at the intersection of space manufacturing and biotechnology showcases how orbital platforms can directly enable new classes of therapeutics. We’re thrilled to support LambdaVision as they translate their success in orbit into clinical impact here on Earth.”
Ariel Ekblaw, Ph.D., Founding Partner of Aurelia Foundry Fund
“LambdaVision demonstrates the potential for space-enabled biotech to deliver transformative therapies on Earth. We’re excited to support their journey as they scale their microgravity manufacturing platform toward clinical impact.”
Rob Desborough, Partner at Seraphim Space
